Comparable results were found in breast cancer patients, thyroid cancer patients with multiple tumors or in those receiving I131 therapy, breast cancer patients diagnosed with the HER2+ or TNBC genotype or those being treated with chemotherapy, and patients with metastasis. This evidence concerns the gene ERBB2 and thyroid cancer.